Corona Remedies IPO Review
Corona Remedies IPO has been reviewed by 15 analysts, and the overall consensus is Strong Apply — carrying a score of 100. Out of the 15 analysts who have covered this IPO, 15 recommend subscribing — reflecting a broadly positive view from the analyst community.
The issue is priced in the band of ₹₹1,008 – ₹1,062 per share, with a minimum application size of 14 shares. Subscription ran from 08 Dec 2025 to 10 Dec 2025. The issue size is ₹655 crore, entirely an offer for sale — the company receives none of the proceeds. As of now, the grey market premium (GMP) for Corona Remedies IPO is quoting at ₹300 (484%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Analyst verdict & score
One score out of 100, aggregated from every analyst verdict tracked for this issue. How it's calculated
Higher consensus indicates broader analyst agreement.
Detailed review
What the analyst reports say, grouped by the question you're likely asking.
General review
Listing gains
Short-term strategy
Long-term strategy
How this is written: an AI-assisted summary of the 17 analyst reports listed below. It reports their views; IPO Guru does not make buy or sell recommendations.
Analyst reviews
Ordered by each analyst's track record over the past year; analysts still building one are listed last.
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Corona Remedies IPO?
The analyst consensus for Corona Remedies IPO tracked on this page is Strong Apply, with a score of 100/100. Out of 15 analysts who have reviewed this IPO, 15 recommend subscribing. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of 100 mean for Corona Remedies IPO?
The score of 100 is an aggregate of all analyst ratings tracked for Corona Remedies IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Read the individual analyst verdicts above for more context.
What was the actual listing price of Corona Remedies IPO?
Corona Remedies IPO listed on December 15, 2025 at ₹1470, against the issue price of ₹1062 — a gain of +38.42% (₹408 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Corona Remedies IPO?
Corona Remedies IPO was priced at ₹₹1,008 – ₹1,062 per share. The minimum lot size is 14 shares. Subscription ran from 08 Dec 2025 to 10 Dec 2025.
Explore Corona Remedies IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
